文献速递淋巴瘤

原发性HHV8阴性渗出性淋巴瘤:一种预后良好的大B细胞淋巴瘤

Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.
PubMed 文献 · Blood Adv · 2020-01-01

该回顾性研究纳入日本95例渗出性淋巴瘤(EBL)患者,其中64例HHV8阴性。原发性HHV8阴性EBL多见于老年患者(中位年龄77岁),胸膜积液最常见(77%),非生发中心B细胞亚型为主。接受蒽环类为基础化疗后预后良好,2年总生存率84.7%,无进展生存率73.8%。

要点

  • 原发性HHV8阴性EBL多见于老年患者,中位年龄77岁,胸膜积液最常见。
  • 非生发中心B细胞亚型占多数(30/38例可评估患者)。
  • 蒽环类为基础化疗后预后良好,2年OS 84.7%,PFS 73.8%。

核心结论

  • 日本大多数EBL病例为HHV8阴性,多见于老年患者,非生发中心B细胞亚型为主,蒽环类为基础化疗后预后良好。

研究设计与样本

  • 日本回顾性研究,纳入95例EBL患者(无论HHV8状态),其中69例检测HHV8,64例阴性。

主要发现

  • 原发性HHV8阴性EBL诊断时中位年龄77岁(范围57-98岁),58例检测HIV的患者均为阴性。
  • 胸膜积液最常见(77%),所有病例至少表达一种泛B细胞抗原(CD19、CD20或CD79a)。
  • 38例可评估患者中30例为非生发中心B细胞(non-GCB)肿瘤,45例中6例EB病毒编码小RNA阳性。
  • 64例HHV8阴性患者中56例在诊断后3个月内开始全身治疗,48例接受CHOP或CHOP样方案(联合或不联合利妥昔单抗)作为主要治疗。
  • 总体缓解率95%,完全缓解率73%;中位随访25个月,2年总生存率84.7%,无进展生存率73.8%。

临床怎么用

  • 原发性HHV8阴性EBL可考虑蒽环类为基础的化疗(如CHOP或CHOP样方案),预后较好。

局限性

  • 回顾性研究设计,样本来自日本,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary effusion-based lymphoma (EBL) presents as a malignant effusion in a body cavity. The clinicopathologic features and prognosis of primary human herpesvirus 8 (HHV8)-negative EBL remain unclear. We therefore conducted a retrospective study of 95 patients with EBL, regardless of HHV8 status, in Japan. Of 69 patients with EBL tested for HHV8, a total of 64 were negative. The median age of patients with primary HHV8-negative EBL at diagnosis was 77 years (range, 57-98 years); all 58 tested patients were negative for HIV. Primary HHV8-negative EBL was most commonly diagnosed in pleural effusion (77%). Expression of at least 1 pan B-cell antigen (CD19, CD20, or CD79a) was observed in all cases. According to the Hans algorithm, 30 of the 38 evaluated patients had nongerminal center B-cell (non-GCB) tumors. Epstein-Barr virus-encoded small RNA was positive in 6 of 45 patients. In 56 of 64 HHV8-negative patients, systemic therapy was initiated within 3 months after diagnosis. Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimens with or without rituximab (n = 48) were the most common primary treatments. The overall response and complete response rates were 95% and 73%, respectively. Three patients did not progress without systemic treatment for a median of 24 months. With a median 25-month follow-up, the 2-year overall survival and progression-free survival rates were 84.7% and 73.8%. Sixteen patients died; 12 were lymphoma-related deaths. Thus, most EBL cases in Japan are HHV8-negative and affect elderly patients. The non-GCB subtype is predominant. Overall, primary HHV8-negative EBL exhibits a favorable prognosis after anthracycline-based chemotherapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kaji D, Ota Y, Sato Y, et al. Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood Adv. 2020. PMID: 32936906. doi:10.1182/bloodadvances.2020002293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。